Brickell Biotech, Inc. BBI
We take great care to ensure that the data presented and summarized in this overview for Brickell Biotech, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BBI
Top Purchases
Top Sells
About BBI
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Insider Transactions at BBI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 06
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
320
+0.03%
|
$0
$0.89 P/Share
|
|
May 03
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
324
+0.03%
|
$0
$0.91 P/Share
|
|
May 02
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
2,222
+0.18%
|
$0
$0.91 P/Share
|
|
May 01
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
162,351
+11.72%
|
$0
$0.92 P/Share
|
|
Apr 23
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
343
+0.03%
|
$0
$0.91 P/Share
|
|
Apr 22
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
16,908
+1.57%
|
$0
$0.9 P/Share
|
|
Apr 19
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
4,277
+0.41%
|
$0
$0.91 P/Share
|
|
Apr 10
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
1,000
+0.1%
|
$0
$0.88 P/Share
|
|
Apr 09
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
2,188
+0.21%
|
$0
$0.88 P/Share
|
|
Apr 05
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
1,050
+0.1%
|
$0
$0.91 P/Share
|
|
Apr 04
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
3,400
+0.33%
|
$0
$0.91 P/Share
|
|
Apr 03
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
12,928
+1.24%
|
$0
$0.91 P/Share
|
|
Apr 01
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
354
+0.03%
|
$0
$0.89 P/Share
|
|
Mar 28
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
2,586
+0.25%
|
$0
$0.9 P/Share
|
|
Mar 27
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
51,634
+4.84%
|
$0
$0.9 P/Share
|
|
Mar 20
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
287
+0.03%
|
$0
$0.91 P/Share
|
|
Mar 19
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
10
+0.0%
|
$0
$0.9 P/Share
|
|
Mar 13
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
9,126
+0.94%
|
$0
$0.92 P/Share
|
|
Mar 12
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
1,500
+0.16%
|
$0
$0.91 P/Share
|
|
Mar 11
2024
|
Exploration Capital, LLC |
BUY
Open market or private purchase
|
Direct |
5,703
+0.59%
|
$0
$0.91 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 110K shares |
|---|---|
| Open market or private purchase | 573K shares |
| Payment of exercise price or tax liability | 43.2K shares |
|---|---|
| Open market or private sale | 110 shares |
| Open market or private purchase | 30K shares |